Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters

Fertility and Sterility

Volumn 93, Issue 4, 2010, Pages 1227-1233

  Pamuk, Baris Onder ^a   Torun, Ayse Nur ^a   Kulaksizoglu, Mustafa ^a   Ertugrul, Derun ^a   Ciftci, Ozgur ^a   Kulaksizoglu, Sevsen ^a   Yildirim, Erkan ^a   Demirag, Nilgun Guvener ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

asymmetric dimethylarginine; carotid intima media thickness; Polycystic ovary syndrome; subclinical atherosclerosis

Indexed keywords

ANDROGEN; C REACTIVE PROTEIN; CHOLESTEROL; ESTRADIOL; FIBRINOGEN; FOLLITROPIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; N(G),N(G) DIMETHYLARGININE; PRASTERONE SULFATE; THYROXINE; TRIACYLGLYCEROL;

ADULT; ANDROGEN BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTICLE; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ESTRADIOL BLOOD LEVEL; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; FREE THYROXINE INDEX; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LUTEINIZING HORMONE BLOOD LEVEL; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRASTERONE SULFATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL; VEIN PUNCTURE;

ADOLESCENT; ADULT; ARGININE; ENERGY METABOLISM; FEMALE; HUMANS; OBESITY; POLYCYSTIC OVARY SYNDROME; PROSPECTIVE STUDIES; TUNICA INTIMA; TUNICA MEDIA; YOUNG ADULT;

EID: 77049092981     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.10.073     Document Type: Article

References (72)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 333 (1995) 853-861
2. Lobo R.A., and Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 132 (2000) 989-993
3. Chang R.J., Nakamura R.M., Judd H.L., and Kaplan S.A. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab 57 (1983) 356-359
4. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
5. Legro R.S., Kunselman A.R., Dodson W.C., and Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
6. Ovalle F., and Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77 (2002) 1095-1105
7. Wild R.A., Painter P.C., Coulson P.B., Carruth K.B., and Ranney G.B. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 61 (1985) 946-951
8. Holte J., Gennarelli G., Berne C., Bergh T., and Lithell H. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a pre-hypertensive state?. Hum Reprod 11 (1996) 23-28
9. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
10. Pierpoint T., McKeigue P.M., Isaacs A.J., Wild S.H., and Jacobs H.S. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 51 (1998) 581-586
11. Ikeda H., Takajo Y., Murohara T., Ichiki K., Adachi H., Haramaki N., et al. Platelet-derived nitric oxide and coronary risk factors. Hypertension 35 (2000) 904-907
12. Cooke J.P., and Dzau V.J. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med 48 (1997) 489-509
13. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N Engl J Med 329 (1993) 2002-2012
14. Miyazaki H., Matsuoka H., Cooke J.P., Usui M., Ueda S., Okuda S., et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99 (1999) 1141-1146
15. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23 (2003) 1455-1459
16. Abbasi F., Asagmi T., Cooke J.P., Lamendola C., McLaughlin T., Reaven G.M., et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 88 (2001) 1201-1203
17. Boger R.H., Bode-Boger S.M., Szuba A., Tsao P.S., Chan J.R., Tangphao O., et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98 (1998) 1842-1847
18. Zoccali C., Bode-Boger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
19. Gorenflo M., Zheng C., Werle E., Fiehn W., and Ulmer H.E. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 37 (2001) 489-492
20. Valkonen V.P., Paiva H., Salonen J.T., Lakka T.A., Lehtimaki T., Laakso J., et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358 (2001) 2127-2128
21. Krempl T.K., Maas R., Sydow K., Meinertz T., Boger R.H., and Kahler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 26 (2005) 1846-1851
22. Crouse III J.R., Craven T.E., Hagaman A.P., and Bond M.G. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation 92 (1995) 1141-1147
23. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., and Wolfson Jr. S.K. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340 (1999) 14-22
24. Guzick D.S., Talbott E.O., Sutton-Tyrrell K., Herzog H.C., Kuller L.H., and Wolfson Jr. S.K. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 174 (1996) 1224-1229 [discussion 1229-32]
25. Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 20 (2000) 2414-2421
26. Lakhani K., Hardiman P., and Seifalian A.M. Intima-media thickness of elastic and muscular arteries of young women with polycystic ovaries. Atherosclerosis 175 (2004) 353-359
27. Zoccali C., Benedetto F.A., Maas R., Mallamaci F., Tripepi G., Malatino L.S., et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13 (2002) 490-496
28. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
29. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
30. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
31. Barth J.D. An update on carotid ultrasound measurement of intima-media thickness. Am J Cardiol 89 (2002) 32B-38B discussion 8B-9B
32. Fallo F., Camporese G., Capitelli E., Andreozzi G.M., Mantero F., and Lumachi F. Ultrasound evaluation of carotid artery in primary hyperparathyroidism. J Clin Endocrinol Metab 88 (2003) 2096-2099
33. Sam S., and Dunaif A. Polycystic ovary syndrome: syndrome XX?. Trends Endocrinol Metab 14 (2003) 365-370
34. Talbott E., Clerici A., Berga S.L., Kuller L., Guzick D., Detre K., et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol 51 (1998) 415-422
35. Conway G.S., Agrawal R., Betteridge D.J., and Jacobs H.S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 37 (1992) 119-125
36. Sydow K., Schwedhelm E., Arakawa N., Bode-Boger S.M., Tsikas D., Hornig B., et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 57 (2003) 244-252
37. Charitidou C., Farmakiotis D., Zournatzi V., Pidonia I., Pegiou T., Karamanis N., et al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis 196 (2008) 958-965
38. Heutling D., Schulz H., Nickel I., Kleinstein J., Kaltwasser P., Westphal S., et al. Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. J Clin Endocrinol Metab 93 (2008) 82-90
39. Demirel F., Bideci A., Cinaz P., Camurdan M.O., Biberoglu G., Yesilkaya E., et al. Serum leptin, oxidized low density lipoprotein and plasma asymmetric dimethylarginine levels and their relationship with dyslipidaemia in adolescent girls with polycystic ovary syndrome. Clin Endocrinol (Oxf) 67 (2007) 129-134
40. Pignoli P., Tremoli E., Poli A., Oreste P., and Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 74 (1986) 1399-1406
41. Postiglione A., Rubba P., De Simone B., Patti L., Cicerano U., and Mancini M. Carotid atherosclerosis in familial hypercholesterolemia. Stroke 16 (1985) 658-661
42. Ebrahim S., Papacosta O., Whincup P., Wannamethee G., Walker M., Nicolaides A.N., et al. Carotid plaque, intima media thickness, cardiovascular risk factors, and prevalent cardiovascular disease in men and women: the British Regional Heart Study. Stroke 30 (1999) 841-850
43. Howard G., Manolio T.A., Burke G.L., Wolfson S.K., and O'Leary D.H. Does the association of risk factors and atherosclerosis change with age? An analysis of the combined ARIC and CHS cohorts. The Atherosclerosis Risk in Communities (ARIC) and Cardiovascular Health Study (CHS) investigators. Stroke 28 (1997) 1693-1701
44. Takami R., Takeda N., Hayashi M., Sasaki A., Kawachi S., Yoshino K., et al. Body fatness and fat distribution as predictors of metabolic abnormalities and early carotid atherosclerosis. Diabetes Care 24 (2001) 1248-1252
45. De Michele M., Panico S., Iannuzzi A., Celentano E., Ciardullo A.V., Galasso R., et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke 33 (2002) 2923-2928
46. Rajala U., Laakso M., Paivansalo M., Pelkonen O., Suramo I., and Keinanen-Kiukaanniemi S. Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab 87 (2002) 5092-5097
47. Wagenknecht L.E., D'Agostino Jr. R., Savage P.J., O'Leary D.H., Saad M.F., and Haffner S.M. Duration of diabetes and carotid wall thickness. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 28 (1997) 999-1005
48. Golden S.H., Maguire A., Ding J., Crouse J.R., Cauley J.A., Zacur H., et al. Endogenous postmenopausal hormones and carotid atherosclerosis: a case-control study of the atherosclerosis risk in communities cohort. Am J Epidemiol 155 (2002) 437-445
49. Talbott E.O., Zborowski J.V., Rager J.R., Boudreaux M.Y., Edmundowicz D.A., and Guzick D.S. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
50. Lakhani K., Constantinovici N., Purcell W.M., Fernando R., and Hardiman P. Internal carotid artery haemodynamics in women with polycystic ovaries. Clin Sci (Lond) 98 (2000) 661-665
51. Meyer C., McGrath B.P., and Teede H.J. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 90 (2005) 5711-5716
52. Orio Jr. F., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., et al. Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 4588-4593
53. Vryonidou A., Papatheodorou A., Tavridou A., Terzi T., Loi V., Vatalas I.A., et al. Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 2740-2746
54. Meyer C., McGrath B.P., Cameron J., Kotsopoulos D., and Teede H.J. Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 4630-4635
55. Barrett-Connor E., and Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study. Circulation 91 (1995) 1757-1760
56. Ng M.K., Nakhla S., Baoutina A., Jessup W., Handelsman D.J., and Celermajer D.S. Dehydroepiandrosterone, an adrenal androgen, increases human foam cell formation: a potentially pro-atherogenic effect. J Am Coll Cardiol 42 (2003) 1967-1974
57. Furuki K., Adachi H., Matsuoka H., Enomoto M., Satoh A., Hino A., et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis 191 (2007) 206-210
58. Norman R.J., Masters L., Milner C.R., Wang J.X., and Davies M.J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 16 (2001) 1995-1998
59. Burghen G.A., Givens J.R., and Kitabchi A.E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 50 (1980) 113-116
60. Nestler J.E., Jakubowicz D.J., de Vargas A.F., Brik C., Quintero N., and Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83 (1998) 2001-2005
61. Stuhlinger M.C., Abbasi F., Chu J.W., Lamendola C., McLaughlin T.L., Cooke J.P., et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287 (2002) 1420-1426
62. Stuhlinger M.C., Tsao P.S., Her J.H., Kimoto M., Balint R.F., and Cooke J.P. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104 (2001) 2569-2575
63. Boger R.H., Bode-Boger S.M., Sydow K., Heistad D.D., and Lentz S.R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20 (2000) 1557-1564
64. Paroni R., Fermo I., Fiorina P., and Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 28 (2005) 389-394
65. Jonasson T.F., Hedner T., Hultberg B., and Ohlin H. Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease. Eur J Clin Invest 33 (2003) 543-549
66. Kelly C.C., Lyall H., Petrie J.R., Gould G.W., Connell J.M., and Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 2453-2455
67. Bermudez E.A., Rifai N., Buring J., Manson J.E., and Ridker P.M. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arterioscler Thromb Vasc Biol 22 (2002) 1668-1673
68. Danesh J., Muir J., Wong Y.K., Ward M., Gallimore J.R., and Pepys M.B. Risk factors for coronary heart disease and acute-phase proteins. A population-based study. Eur Heart J 20 (1999) 954-959
69. Bickerton A.S., Clark N., Meeking D., Shaw K.M., Crook M., Lumb P., et al. Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 58 (2005) 151-154
70. Mohlig M., Spranger J., Osterhoff M., Ristow M., Pfeiffer A.F., Schill T., et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150 (2004) 525-532
71. Atiomo W.U., Bates S.A., Condon J.E., Shaw S., West J.H., and Prentice A.G. The plasminogen activator system in women with polycystic ovary syndrome. Fertil Steril 69 (1998) 236-241
72. Dahlgren E., Janson P.O., Johansson S., Lapidus L., Lindstedt G., and Tengborn L. Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 61 (1994) 455-460